TriSalus Life Sciences (NASDAQ:TLSI) Earns Buy Rating from Canaccord Genuity Group

Canaccord Genuity Group reiterated their buy rating on shares of TriSalus Life Sciences (NASDAQ:TLSI) in a research report sent to investors on Friday morning,Benzinga reports. Canaccord Genuity Group currently has a $11.00 target price on the stock.

TLSI has been the subject of a number of other research reports. Roth Mkm reissued a “buy” rating and set a $11.00 target price on shares of TriSalus Life Sciences in a report on Friday, January 24th. Cantor Fitzgerald started coverage on TriSalus Life Sciences in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 price objective for the company. Finally, Lake Street Capital began coverage on shares of TriSalus Life Sciences in a research note on Thursday, February 13th. They set a “buy” rating and a $10.00 target price on the stock. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $11.56.

TriSalus Life Sciences Stock Performance

Shares of NASDAQ TLSI opened at $5.62 on Friday. The firm has a fifty day moving average of $5.40 and a 200 day moving average of $4.73. The firm has a market cap of $171.37 million, a PE ratio of -2.26 and a beta of 0.48. TriSalus Life Sciences has a one year low of $3.50 and a one year high of $10.42.

TriSalus Life Sciences (NASDAQ:TLSI) last released its earnings results on Thursday, March 27th. The company reported ($0.35) EPS for the quarter, hitting analysts’ consensus estimates of ($0.35). The company had revenue of $8.26 million for the quarter, compared to analysts’ expectations of $8.12 million. On average, equities analysts predict that TriSalus Life Sciences will post -1.55 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Sean Murphy purchased 15,000 shares of the company’s stock in a transaction dated Monday, January 27th. The stock was acquired at an average price of $5.31 per share, with a total value of $79,650.00. Following the purchase, the insider now directly owns 182,732 shares in the company, valued at approximately $970,306.92. This represents a 8.94 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Mary T. Szela purchased 4,826 shares of the business’s stock in a transaction dated Monday, January 27th. The shares were purchased at an average price of $5.42 per share, with a total value of $26,156.92. Following the acquisition, the chief executive officer now directly owns 429,503 shares in the company, valued at approximately $2,327,906.26. The trade was a 1.14 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 54,856 shares of company stock valued at $294,608 in the last three months. 32.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Walleye Capital LLC acquired a new position in shares of TriSalus Life Sciences in the 3rd quarter valued at $66,000. Renaissance Technologies LLC purchased a new stake in TriSalus Life Sciences in the 4th quarter valued at about $67,000. Virtu Financial LLC acquired a new position in TriSalus Life Sciences in the third quarter valued at about $92,000. Vestcor Inc purchased a new position in TriSalus Life Sciences during the third quarter worth about $108,000. Finally, Connective Capital Management LLC acquired a new stake in shares of TriSalus Life Sciences during the fourth quarter valued at about $140,000. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.